When Christian Earl was six weeks old, his mother did not think his eyes looked right, so she took him to Loyola University Medical Center for an evaluation.
Aberrometry-Based Refraction: Enough for Surgical Planning?
Intraoperative wavefront aberrometry may not provide consistent results and should not be relied on as the sole guidance for intraoperative surgical planning during cataract surgery. Medscape Medical News
Uncategorized
Surgeons, patients less likely to accept premium IOLs with high copayments
Patients were less likely to accept advanced technology IOLs with higher copayments, according to a study. In addition, surgeons were less likely to suggest premium IOLs as copayments rose. The study included 370 cataract surgeons and 700 patients unde…
10 Cool, Amazing Gadgets and Trends to Help Your Practice
Many unique technological advances and new requirements of medical practices are quickly changing the way practices operate. Will you recognize your practice in a few years’ time? Medscape Business of Medicine
Uncategorized
Glaucoma reoperation rates higher following trabeculectomy than tube shunt
Reoperation rates for glaucoma were found to be higher in patients who underwent trabeculectomy with mitomycin C than in patients who underwent tube shunt surgery, according to data from the Tube Versus Trabeculectomy Study. A total 212 patients were included in the TVT Study. Patients were randomized into two groups — 107 patients in the tube shunt group (350 mm2 Baerveldt glaucoma implant) and 105 patients in the trabeculectomy with MMC group (0.4 mg/mL). Outcomes were measured for patients whose assigned treatment failed and in whom additional glaucoma surgery was (Read more...)
Uncategorized
Treat-and-extend bevacizumab improves vision in treatment of BRVO-related macular edema
Intravitreal bevacizumab administered in a treat-and-extend regimen compared favorably to as-needed injections of ranibizumab in the treatment of branch retinal vein occlusion-associated macular edema, according to a study. “Notwithstand¬ing the retrospective and uncontrolled nature of our study, our data suggest that [intravitreal bevacizumab] delivered in a [treat-and-extend] regimen is a cost-effective strategy that offers excel¬lent visual and anatomic outcomes compared to the PRN ranibizumab strategies employed in phase 3 clinical trials,” the study authors wrote.